GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Vivesto AB (OTCPK:OASMY) » Definitions » ROE % Adjusted to Book Value

Vivesto AB (Vivesto AB) ROE % Adjusted to Book Value : -616.58% (As of Dec. 2023)


View and export this data going back to 2015. Start your Free Trial

What is Vivesto AB ROE % Adjusted to Book Value?

Vivesto AB's ROE % for the quarter that ended in Dec. 2023 was -117.15%. Vivesto AB's PB Ratio for the quarter that ended in Dec. 2023 was 0.19. Vivesto AB's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2023 was -616.58%.


Vivesto AB ROE % Adjusted to Book Value Historical Data

The historical data trend for Vivesto AB's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vivesto AB ROE % Adjusted to Book Value Chart

Vivesto AB Annual Data
Trend Apr14 Apr15 Apr16 Apr17 Apr18 Apr19 Apr20 Dec21 Dec22 Dec23
ROE % Adjusted to Book Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only -10.29 -0.43 -10.21 -106.83 -260.53

Vivesto AB Quarterly Data
Jan19 Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -297.49 -83.13 - - -616.58

Competitive Comparison of Vivesto AB's ROE % Adjusted to Book Value

For the Drug Manufacturers - Specialty & Generic subindustry, Vivesto AB's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vivesto AB's ROE % Adjusted to Book Value Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Vivesto AB's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Vivesto AB's ROE % Adjusted to Book Value falls into.



Vivesto AB ROE % Adjusted to Book Value Calculation

Vivesto AB's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2023 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-49.50% / 0.19
=-260.53%

Vivesto AB's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2023 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-117.15% / 0.19
=-616.58%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Vivesto AB ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of Vivesto AB's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Vivesto AB (Vivesto AB) Business Description

Traded in Other Exchanges
Address
Gustav III:s Boulevard 46, 5th Floor, Solna, SWE, SE-169 73
Vivesto AB is a research and development company that develops new treatment options for patients suffering from difficult-to-treat cancer. The company's product development leverages its proprietary technology platforms to manufacture novel drug formulations that are intended to demonstrate improved properties in comparison with current alternatives, which can lead to a reduced side-effect profile and an expanded therapeutic area. The company has a portfolio of projects targeting cancer treatments.

Vivesto AB (Vivesto AB) Headlines

From GuruFocus